Table 3.
Follow-up delta-values (anthropometrics and biomarkers) for the participants included in the follow-up analysis.
| All | P-value* | Group A | Group B | P-value** | |
|---|---|---|---|---|---|
| N | 89 | 65 (73%) | 23 (26%) | ||
| BMI-SDS, kg/m2 | −0.3 (0.5) | <0.01 | −0.6 (0.4) | 0.2 (0.3) | <0.01 |
| DEXA–FM, % | −2.2 (5.9) | <0.01 | −4.0 (5.7) | 2.6 (2.8) | <0.01 |
| Cholesterol, mmol/L | −0.1 (0.5) | 0.1 | −0.1 (0.5) | 0.0 (0.6) | 0.61 |
| HDL, mmol/L | 0.0 (0.2) | 0.37 | 0.0 (0.2) | −0.1 (0.2) | <0.01 |
| LDL, mmol/L | −0.2 (0.5) | <0.01 | −0.2 (0.4) | 0.0 (0.6) | 0.09 |
| Triglycerides, mmol/L | 0.0 (0.6) | 0.84 | −0.1 (0.5) | 0.3 (0.6) | 0.01 |
| LDH, mmol/L | −16.9 (33.0) | <0.01 | −18.9 (34.3) | −11 (28.9) | 0.31 |
| ALAT, IU/L | 0.9 (16.3) | 0.61 | −0.6 (7.8) | 4.2 (29.3) | 0.45 |
| Bilirubin, μmol/L | 1.8 (2.9) | <0.01 | 2.0 (3.2) | 1.4 (1.9) | 0.3 |
| Fasting glucose, mmol/L | 0.0 (0.4) | 0.52 | 0.0 (0.4) | 0.1 (0.4) | 0.39 |
| HbA1c, mmol/L | −0.1 (0.4) | 0.04 | −0.1 (0.4) | 0.0 (0.4) | 0.42 |
| TSH, 10−3 IU/L | −0.1 (1.0) | 0.2 | −0.2 (1.1) | −0.1 (0.8) | 0.72 |
| T3, pmol/L | −0.2 (0.7) | 0.03 | −0.3 (0.7) | 0.0 (0.7) | 0.1 |
| Albumin, g/L | −0.2 (2.6) | 0.52 | 0.0 (2.7) | −0.9 (2.1) | 0.11 |
| Creatinine, μmol/L | 3.6 (5.6) | <0.01 | 3.6 (5.4) | 3.6 (6.2) | 0.98 |
| Carbamide, mmol/L | 0.4 (1.3) | <0.01 | 0.2 (1.3) | 0.7 (1.2) | 0.11 |
| Uric acid, mmol/L | 0.0 (0.05) | 0.98 | −0.01 (0.05) | 0.02 (0.03) | <0.01 |
Group A consists of the children who reduced BMI-SDS and Group B consists of the children who increased BMI-SDS.
The p-values
*
represent differences between baseline and last measurement.
The p-values
**
represent differences between group A and B. All data are reported as mean value with standard deviations (SD).